...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Free
Message: Peter Libby

Dr Libby adds tremendous gravitas to our story. It is worth the time to understand his devotion to the role of inflammation in CVD. A look at our regulation of inflammatory markers may account for his involvement ? This is a huge plus for US Bio Analysts scrutiny and also FDA if/ when we show good BOM results. 

Share
New Message
Please login to post a reply